Clinical Trial Search

Primary: Change From Baseline in HbA1c (Glycosylated Hemoglobin) at Week 18 — -0.07; -0.54 percent — p=< 0.0001

Primary: Number of Participants With All-cause Mortality — 64; 61; 40; 44 participants — p=0.05

Primary: Geometric Mean Titer 30 Days After the Last Study Vaccination — 235.44; 345.50; 652.99; 227.19 Titers

Primary: Cure Rate at End of Therapy — 86.7; 87.7 Percentage of Participants

Primary: Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms — 0.295; 0.012 Proportion of participants — p=< 0.0001

Primary: Disease-Free Survival (DFS) [Number of Events] — 379; 320; 563; 624 Participants

Primary: Percent Change From the Parent Study Baseline in Cortical Thickness at the Distal Radius by HR-pQCT — -5.5; -1.8 Percent change — p=0.0766

Primary: Percentage of Treatment Success Patients at Week 6, ITT (Intent to Treat) Population — 59.2; 71.8 Percentage of Participants — p=0.0357

Primary: Number of Participants With Any Serious Adverse Event (SAE) and Any Non Serious Adverse Event — 13; 75 participants

Primary: Number of Clinical Malaria Episodes Per Year of Follow-up — 0.61; 0.68; 0.64; 0.59 Episodes per PYAR — p=0.8097

Primary: Number of Participants With Reactogenicity (Solicited) Adverse Events (AEs) — 40; 62; 12; 15 participants

Primary: Participants With Treatment-Emergent Adverse Events (AEs) — 218; 1; 3; 60 participants

Primary: Progression Free Survival — 389; 334 days — p=0.039

Primary: Change in Left Ventricular (LV) Systolic Function Expressed as Left Ventricular Ejection Fraction (LVEF) Between Baseline and 12-month Follow-up — 36; 37; 39; 35…

Primary: HbA1c (Glycosylated Haemoglobin) at Month 12 — 8.45; 8.55; 8.63; 7.64 percentage (%) of total haemoglobin